PATH | VRL
Menu

Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal

This article, published in The New England Journal of Medicine, reports the results of a study evaluating the efficacy of typhoid conjugate vaccine (TCV) in Nepal. The results indicate that the TCV is safe and 81.6 percent efficacious in children aged 9 months to 16 years old. The authors conclude that a single-dose of TCV is immunogenic and efficacious in children in an endemic setting. These findings uphold the recent recommendations of the World Health Organization to use TCV in high-burden settings and to immunize children who are 9 months to 15 years of age.

Author: Shakya M, Colin-Jones R, Theiss-Nyland K, et al.

Published: 2019

» Visit web page (English)

(Located at www.nejm.org)

Citation: Shakya M, Colin-Jones R, Theiss-Nyland K, et al. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. The New England Journal of Medicine. 2019;381:2209-2218. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Typhoid

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Asia